{"schema_version":"1.0","type":"article","title":"US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.md","lang":"en","date":"2026-09-28","publish_at":"2026-09-28T08:00:00+08:00","updated_at":"2026-09-28","category":"商業分析系列","topic":"商業分析系列","tags":["Johnson & Johnson","DePuy Synthes","Orthopaedics","Business separation","Apollo","United Orthopedic"],"summary":"Why might an orthopaedics business with US$9.2 billion in annual sales lose priority for J&J’s next investment? Growth differences, the value flows in a spin-off versus a sale, and the costs of implants and surgical support explain the economic questions behind the proposed DePuy Synthes separation.","key_points":[],"facts":[],"sections":["【01｜Orthopaedics Is Still Growing, but May Not Get the Next Investment】","【02｜Distributing Shares and Selling for Cash Deliver Different Assets】","【03｜What Would Earn Back a US$20 Billion Investment?】","【04｜Acquiring Orthopaedics Means Acquiring a Surgical Business】","【05｜A Direct Taiwanese Comparison: United Orthopedic】","References"],"references":[{"title":"[1] J&J, intention to separate its orthopaedics business, October 14, 2025.","source":"","date":"","url":""},{"title":"https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business"},{"title":"[2] J&J, second-quarter 2026 Form 10-Q. Reporting period ended June 28, 2026; signature date in the filing: July 23, 2026.","source":"","date":"","url":""},{"title":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm"},{"title":"[3] Bloomberg, reported Apollo talks to acquire J&J’s orthopaedics business, September 11, 2026, 22:26 UTC (September 12 in Taipei). Only publicly accessible paragraphs are cited.","source":"","date":"","url":""},{"title":"https://news.bloomberglaw.com/pharma-and-life-sciences/apollo-global-is-said-in-talks-to-acquire-j-js-orthopedics-unit","source":"","date":"","url":"https://news.bloomberglaw.com/pharma-and-life-sciences/apollo-global-is-said-in-talks-to-acquire-j-js-orthopedics-unit"},{"title":"[4] J&J and Apollo announcement lists reviewed on September 27, 2026. Entries accessible in this review covered September 10–25 and August 11–September 17, respectively. This does not rule out unindexed pages or non-public information.","source":"","date":"","url":""},{"title":"https://www.jnj.com/media-center/press-releases","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases"},{"title":"https://ir.apollo.com/news-events/press-releases","source":"","date":"","url":"https://ir.apollo.com/news-events/press-releases"},{"title":"[5] United Orthopedic, company profile and shareholder information. Accessed September 27, 2026.","source":"","date":"","url":""},{"title":"https://tw.unitedorthopedic.com/about-us","source":"","date":"","url":"https://tw.unitedorthopedic.com/about-us"},{"title":"https://tw.unitedorthopedic.com/investor/shareholder5/","source":"","date":"","url":"https://tw.unitedorthopedic.com/investor/shareholder5/"},{"title":"[6] United Orthopedic, total knee replacement and U2 Knee AiO product pages. Accessed September 27, 2026.","source":"","date":"","url":""},{"title":"https://tw.unitedorthopedic.com/total-knee-replacement/","source":"","date":"","url":"https://tw.unitedorthopedic.com/total-knee-replacement/"},{"title":"https://tw.unitedorthopedic.com/innovation/u2-knee-aio","source":"","date":"","url":"https://tw.unitedorthopedic.com/innovation/u2-knee-aio"},{"title":"[7] SEC Investor.gov, Spin-Offs. Accessed September 27, 2026.","source":"","date":"","url":""},{"title":"https://www.investor.gov/introduction-investing/investing-basics/glossary/spin-offs","source":"","date":"","url":"https://www.investor.gov/introduction-investing/investing-basics/glossary/spin-offs"},{"title":"This article provides industry information and business analysis and does not constitute individualized investment advice.","source":"","date":"","url":""},{"title":"#JohnsonAndJohnson #JNJ #DePuySynthes #Apollo #Orthopaedics #MedicalDevices #MedTech #UnitedOrthopedic #4129 #Drugnews","source":"","date":"","url":""}],"images":[{"alt":"The strategic priorities of J&J and a proposed independent DePuy Synthes. The separation is not completed, and growth and margin improvements remain company expectations.","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation-en/01_%E5%88%86%E9%9B%A2%E7%AD%96%E7%95%A5_EN_v2.png"},{"alt":"Two illustrative routes: distributing equity to existing shareholders or selling to an outside buyer. Shares, business rights and consideration flow to different recipients.","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation-en/02_%E5%88%86%E9%9B%A2%E9%80%94%E5%BE%91_EN_v1.png"},{"alt":"Three evidence levels: reporting on talks, a definitive agreement and a completion announcement. US$20 billion is the valuation attributed to anonymous sources.","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation-en/03_%E6%B4%BD%E8%AB%87%E8%AD%89%E6%93%9A_EN_v2.png"},{"alt":"United Orthopedic’s implants, instruments and manufacturing capabilities are distinguished from transaction relationships, orders and financial benefits that lack direct evidence.","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation-en/04_%E5%8F%B0%E7%81%A3%E8%83%BD%E5%8A%9B_EN_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation-en/01_%E5%88%86%E9%9B%A2%E7%AD%96%E7%95%A5_EN_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-28）。US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?。https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-28-jnj-orthopaedics-separation.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}